ArticleMedicine2026
Pre-frailty and frailty as independent predictors of mortality in U.S. breast cancer survivors: Evidence from the national health interview survey, 1997 to 2018: Frailty and all-cause mortality.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frailty is increasingly recognized as a determinant of poor outcomes in cancer survivorship, yet its prognostic value among breast cancer survivors remains unclear, particularly for pre-frailty. We analyzed data from 22 waves of the national health interview survey (1997-2018), linked to the national death index, encompassing 625,128 adults, including 9941 breast cancer survivors and 615,187 cancer-free participants. Frailty was assessed using a modified fatigue, resistance, ambulation, illness, and loss of weight scale and categorized as robust (score 0), pre-frail (score 1-2), or frail (score 3-5). Kaplan-Meier methods and log-rank tests evaluated survival differences, and Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality, adjusting for sociodemographic, clinical, and cancer-related covariates. Among breast cancer survivors, 78.3% were robust, 13.1% pre-frail, and 8.6% frail, compared with 88.7%, 6.3%, and 5.0% among cancer-free participants. Kaplan-Meier analyses revealed significant survival differences across frailty categories (log-rank P < .001). In fully adjusted models, pre-frailty (HR, 1.44; 95% CI, 1.39-1.51) and frailty (HR, 1.70; 95% CI, 1.49-1.94) were both independently associated with increased mortality relative to robust survivors. Associations were consistent in women and in survivors aged ≥60 years. Among survivors younger than 60 years, frailty remained a strong predictor of mortality (HR, 2.46; 95% CI, 1.52-4.00), whereas pre-frailty did not reach statistical significance. In the small subgroup of male survivors, frailty was not significantly associated with mortality, likely due to limited sample size. Both pre-frailty and frailty independently predict mortality in breast cancer survivors. Systematic frailty screening and targeted interventions may improve survivorship outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.